- PEGs by Application
- PEGs by Structure
-
PEG Linkers
- >PROTAC Linker
- >Methoxy PEG (mPEG)
- >Amine(NH2) PEG
- >DSPE PEG
- >Thiol(SH) PEG
- >Maleimide(Mal) PEG
- >DBCO PEG
- >Azide(N3) PEG
- >Carboxylic Acid(COOH) PEG
- >Acrylate(AC) PEG
- >Cyanine (Cy) PEG
- >NHS ester PEG
- >Biotin PEG
- >Aldehyde (Ald/CHO)PEG
- >Other Lipid PEG
- >Fluorescent (FITC) PEG
- >Cholesterol PEG
- >Hydroxyl(OH) PEG
- >OPSS PEG
- >Acrylamide(ACA) PEG
- >Epoxide (EPO) PEG
- >Hydrazide (HZ) PEG
- >Boc/Fmoc PEG
- > Folic Acid(FA) PEG
- >Lipoic acid(LA) PEG
- >Halide (F,Cl,Br,I) PEG
- >Methacrylate (MA) PEG
- >Rhodamine B(RB) PEG
- >Silane PEG
- >PLGA PEG
- >PCL PEG
- >PLA PEG
- >PEG Sulfonic acid
- >PEG PFP ester
- >PEG TFP ester
- >Benzyl-PEG
- >Aminooxy PEG
- >Hydrocarbons PEG
- >Nitrophenyl Carbonate (NPC) PEG
- >DNP PEG
- >Other PEG
- PEG in mRNA Vaccines
- PEG Raw Material
- Large Scale PEGs
PEGylation is the process of modification of biological molecules by covalent conjugation with polyethylene glycol (PEG). PEGylation is being used as a universal therapeutic technique to provide diverse conjugation with peptides, proteins, antibody fragments, aptamers, enzymes, and small molecules, and has expanded clinical applications for biopharma industries. Dozens of PEGylated drugs are currently on the market for the treatment of cancer, chronic kidney diseases, hepatitis, multiple sclerosis, hemophilia, and gastrointestinal disorders, etc.
PEGylation improves the pharmacokinetics of the molecule (by reducing clearance and increasing half-life), increases the dosing interval, and improves patient convenience compared to non-PEGylated products. In addition, PEGylation of therapeutic agents is medically valuable in reducing immunogenicity, antigenicity, and toxicity, as well as significantly reducing the renal clearance of the drug while maintaining drug efficacy.
Biopharma PEG provides thousands of PEG linkers (PEGylation reagents) - maleimide, pyridyl disulfide, amine, carboxylic acids and NHS esters functionalized PEG, such as nh2-peg-nh2, mPEG-NH2, which can be linked with proteins, typical reactive amino acids include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine, tyrosine. Also, Biochempeg provides custom PEG synthesis services to meet our customer's different PEGylation needs.
References:
1. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315-29. doi: 10.2165/00063030-200822050-00004. PMID: 18778113.
2. Ramos de la Peña, Ana Mayela & Aguilar, Oscar. (2020). Progress and Challenges in PEGylated Proteins Downstream Processing: A Review of the Last 8 Years. International Journal of Peptide Research and Therapeutics. 26. 10.1007/s10989-019-09840-4.
3. Poovi, Ganesan and Narayanasamy Damodharan. “Pegylation : Concept , Application , Characterization , PEG Reagents and its Various Shapes and Functionalization Agent.” (2018).
| Catalog No. | Name | Structure | M.W. | Purity | Buy |
| MF001096 | mPEG-DSPE |
|
≥95% | ||
| LP096072 | DSPE-PEG-Galactose |
|
≥95% | ||
| MD005005 | NH2-PEG8-NH2 |
|
412.5 | ≥95% | |
| MD005005 | NH2-PEG12-NH2 |
|
588 | ≥95% | |
| MD001003 | mPEG5-SH |
|
268.4 | ≥95% | |
| MD001003 | mPEG6-SH |
|
312.42 | ≥95% | |
| MD068121 | Boc-NH-PEG3-CH2COOH |
|
307.34 | ≥95% | |
| MD069016 | Fmoc-NH-PEG4-COOH |
|
487.5 | ≥95% |